Fig. 5.
![Fig. 5. Effects of group I antagonists on the second [Ca2+]i peak in thrombasthenic platelets. Platelets obtained from a patient with Glanzmann thrombathenia were preincubated with 10 μmol/L of each group I antagonist and then stimulated with 0.03 U/mL thrombin. (A) None. (B) FK633. (C) FR169824.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/92/10/10.1182_blood.v92.10.3675/4/blod42238005x.jpeg?Expires=1735550753&Signature=pken62WiXu8KacKGrPnwu4T7LI~Lcs8eTRMBT3ptWxVAJDYOuxbbdbXDxVbrE9WqVV2oYIV3IMKGPvXH4Ih05k~zCaku-BTub7hLk2h2RennUpHYC--1igPXf8SZKHsbyExRphGiq5lKV4T9UNWbSZNcxJvzwztOc2wKLL6VMnKFrhq4QEVz5ZG1m0mAJ1iKCoF4PotEmgaSlF~4TCfYEc17V8cqjnkrRTeTK3-i6lHmypfWazgtw9r9CbrZMkh82huDi2h-O~dq7XWjh0Gkoktu7yyP6iJTyLF9wi93cOLjzXG-eieSt~KKHGhrZjElAEViLJjt~w~ykqCfXK9-Bg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Effects of group I antagonists on the second [Ca2+]i peak in thrombasthenic platelets. Platelets obtained from a patient with Glanzmann thrombathenia were preincubated with 10 μmol/L of each group I antagonist and then stimulated with 0.03 U/mL thrombin. (A) None. (B) FK633. (C) FR169824.
